Todd J Zurlinden1, Kennon Heard2,3, Brad Reisfeld1,4. 1. Department of Chemical and Biological Engineering, Colorado State University, Fort Collins, Colorado, 80523-1370. 2. Department of Emergency Medicine, University of Colorado School of Medicine, 12401 E. 17th Avenue Campus Box B-215, Aurora, CO, 80045. 3. Rocky Mountain Poison and Drug Center, Denver, CO, 80204. 4. School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, 80523-1376, USA.
Abstract
AIM: In cases of paracetamol (acetaminophen, APAP) overdose, an accurate estimate of tissue-specific paracetamol pharmacokinetics (PK) and ingested dose can offer health care providers important information for the individualized treatment and follow-up of affected patients. Here a novel methodology is presented to make such estimates using a standard serum paracetamol measurement and a computational framework. METHODS: The core component of the computational framework was a physiologically-based pharmacokinetic (PBPK) model developed and evaluated using an extensive set of human PK data. Bayesian inference was used for parameter and dose estimation, allowing the incorporation of inter-study variability, and facilitating the calculation of uncertainty in model outputs. RESULTS: Simulations of paracetamol time course concentrations in the blood were in close agreement with experimental data under a wide range of dosing conditions. Also, predictions of administered dose showed good agreement with a large collection of clinical and emergency setting PK data over a broad dose range. In addition to dose estimation, the platform was applied for the determination of optimal blood sampling times for dose reconstruction and quantitation of the potential role of paracetamol conjugate measurement on dose estimation. CONCLUSIONS: Current therapies for paracetamol overdose rely on a generic methodology involving the use of a clinical nomogram. By using the computational framework developed in this study, serum sample data, and the individual patient's anthropometric and physiological information, personalized serum and liver pharmacokinetic profiles and dose estimate could be generated to help inform an individualized overdose treatment and follow-up plan.
AIM: In cases of paracetamol (acetaminophen, APAP) overdose, an accurate estimate of tissue-specific paracetamol pharmacokinetics (PK) and ingested dose can offer health care providers important information for the individualized treatment and follow-up of affected patients. Here a novel methodology is presented to make such estimates using a standard serum paracetamol measurement and a computational framework. METHODS: The core component of the computational framework was a physiologically-based pharmacokinetic (PBPK) model developed and evaluated using an extensive set of human PK data. Bayesian inference was used for parameter and dose estimation, allowing the incorporation of inter-study variability, and facilitating the calculation of uncertainty in model outputs. RESULTS: Simulations of paracetamol time course concentrations in the blood were in close agreement with experimental data under a wide range of dosing conditions. Also, predictions of administered dose showed good agreement with a large collection of clinical and emergency setting PK data over a broad dose range. In addition to dose estimation, the platform was applied for the determination of optimal blood sampling times for dose reconstruction and quantitation of the potential role of paracetamol conjugate measurement on dose estimation. CONCLUSIONS: Current therapies for paracetamoloverdose rely on a generic methodology involving the use of a clinical nomogram. By using the computational framework developed in this study, serum sample data, and the individual patient's anthropometric and physiological information, personalized serum and liver pharmacokinetic profiles and dose estimate could be generated to help inform an individualized overdose treatment and follow-up plan.
Authors: Robert B Raffa; Joseph V Pergolizzi; Robert Taylor; John F Decker; Jeffrey T Patrick Journal: Pain Pract Date: 2013-10-28 Impact factor: 3.183
Authors: Jedd D Wolchok; Linda Williams; John T Pinto; Martin Fleisher; Susan E Krown; Wen-Jen Hwu; Philip O Livingston; Christine Chang; Paul B Chapman Journal: Melanoma Res Date: 2003-04 Impact factor: 3.599
Authors: Rotem Ben-Shachar; Yifei Chen; Shishi Luo; Catherine Hartman; Michael Reed; H Frederik Nijhout Journal: Theor Biol Med Model Date: 2012-12-19 Impact factor: 2.432
Authors: James P Sluka; Xiao Fu; Maciej Swat; Julio M Belmonte; Alin Cosmanescu; Sherry G Clendenon; John F Wambaugh; James A Glazier Journal: PLoS One Date: 2016-09-16 Impact factor: 3.240
Authors: Paola Mian; John N van den Anker; Kristel van Calsteren; Pieter Annaert; Dick Tibboel; Marc Pfister; Karel Allegaert; André Dallmann Journal: Clin Pharmacokinet Date: 2020-01 Impact factor: 6.447